SCHEMBL3970588

SCHEMBL3970588

Cc1ccc(C)n(-c2ccccc2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 4/20 0.47
GSK3B P49841 4/20 0.47
MAPK1 P28482 1/20 0.47
KAT2B Q92831 1/20 0.44
PTGS2 P35354 1/20 0.44
GAA P10253 2/20 0.43
ALDH1A1 P00352 7/20 0.43
MAPT P10636 6/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 2/20 0.42
POLB P06746 2/20 0.42
KMT2A Q03164 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
HPGD P15428 2/20 0.42
APEX1 P27695 1/20 0.42
MYC P01106 2/20 0.42
NR4A1 P22736 2/20 0.42
NOTUM Q6P988 1/20 0.42
USP2 O75604 1/20 0.42
HSPA1A P0DMV8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9111100 0.80 GSR (0.41) MAPK1KAT2BALDH1A1MAPTKDM4E
SCHEMBL28529825 0.80 GSK3B (0.44) GSK3AGSK3BMAPK1KAT2BPTGS2
SCHEMBL65301 0.79 MAPT (0.54) GSK3AGSK3BMAPK1PTGS2GAA
SCHEMBL19429628 0.77 ALDH1A1 (0.45) GSK3AGSK3BMAPK1PTGS2GAA
SCHEMBL680769 0.77 ALDH1A1 (0.57) GAAALDH1A1MAPTKDM4EMEN1
SCHEMBL5759510 0.76 KDM4E (0.45) GSK3AGSK3BMAPK1GAAALDH1A1
SCHEMBL9534032 0.76 ALDH1A1 (0.46) GSK3AGSK3BMAPK1KAT2BGAA
SCHEMBL29908822 0.74 ALDH1A1 (0.46) MAPK1KAT2BGAAALDH1A1MAPT
SCHEMBL3968827 0.72 GSK3A (0.48) GSK3AGSK3BMAPK1PTGS2GAA
SCHEMBL19429657 0.72 NPC1 (0.41) GAAALDH1A1MAPTKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299698-A1 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) NOETIX PHARMA LLC 2024-09-12 US claimed
EP-0866656-B1 USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS MARGOLIN SOLOMON B (US) 2007-04-25 EP claimed
EP-1261338-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY CYMAR INC (US) 2006-06-14 EP claimed
EP-1069898-B1 TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS MARGOLIN SOLOMON B (US) 2004-05-12 EP claimed
EP-0813409-B1 TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS MARGOLIN SOLOMON B (US) 2004-05-06 EP claimed
EP-0702551-B1 COMPOSITIONS AND METHODS FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS MARGOLIN SOLOMON B (US) 2002-09-25 EP claimed
US-5962478-A ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE INTERMUNE, INC. 1999-10-05 US claimed
US-20250367178-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF AVALYN PHARMA INC (US) 2025-12-04 US disclosed
US-20250114376-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF AVALYN PHARMA INC. 2025-04-10 US disclosed
EP-4514348-A2 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) Noetix Pharma LLC (US) 2025-03-05 EP disclosed
US-12226407-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof AVALYN PHARMA INC. (US) 2025-02-18 US disclosed
EP-4491180-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF Avalyn Pharma Inc. (US) 2025-01-15 EP disclosed
US-20240299698-A1 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) NOETIX PHARMA LLC 2024-09-12 US disclosed
EP-1261338-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY CYMAR INC (US) 2006-06-14 EP disclosed
US-20050267018-A1 Macrocyclic compounds as inhibitors of viral replication HOFFMANN-LA ROCHE INC. 2005-12-01 US disclosed
US-6956044-B1 Compositions and methods for treatment of epilepsy INTERMUNE, INC. 2005-10-18 US disclosed
US-5962478-A ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE INTERMUNE, INC. 1999-10-05 US disclosed
US-4052509-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-10-04 US disclosed
US-4042699-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-08-16 US disclosed
US-3974281-A ANALGESICS, ANTI-PYRETIC AND ANTI-INFLAMMATORY AGENTS AFFILIATED MEDICAL RESEARCH, INC. (US) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299698-A1 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) CHAT, PNPO, PLPBP GSK3A 347/4885GSK3B 314/4885MAPK1 1053/4885
US-20250114376-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK GSK3A 4152/4885GSK3B 4245/4885MAPK1 1911/4885
US-20250367178-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK GSK3A 4152/4885GSK3B 4245/4885MAPK1 1911/4885
US-20050267018-A1 Macrocyclic compounds as inhibitors of viral replication EIF2AK2, HAVCR2, ZC3HAV1 GSK3A 1361/4885GSK3B 1563/4885MAPK1 2765/4885
US-12226407-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof PLPBP, PIR, PDXK GSK3A 4152/4885GSK3B 4245/4885MAPK1 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.